NCT00514696已完成2 期
Open Label Phase 2 Study of the Safety and Biological Activity of GCS-100 in Subjects With Chronic Lymphocytic Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 8
- 主要终点
- To Evaluate the effect of GCS-100 on markers of apoptosis in subjects with chronic lymphocytic leukemia using physical examinations, vital signs, lab assessments, and adverse event reporting
研究概览
简要总结
The purpose of this study is to evaluate the safety of GCS-100 and the biologic activity of GCS-100 in subjects with chronic lymphocytic leukemia.
详细描述
The primary objective of this study is to evaluate the safety of GCS-100, and effect of GCS-100 on markers of apoptosis in subjects with chronic lymphocytic leukemia. The secondary objective of this study is to evaluate the effect of GCS-100 on peripheral blood leukocyte count in subjects with chronic lymphocytic leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible subjects must meet all of the following criteria:
- •Subject is capable of understanding the purpose and risks of the study and is able to provide written Informed Consent.
- •Subject is male or female, aged at least 18 years.
- •Subject has been diagnosed with chronic lymphocytic leukemia.
- •Subject has Stage II or higher, chronic lymphocytic leukemia that currently requires therapy due to the severity of the disease symptoms and/or to the presence of increasing anemia and/or increasing splenomegaly.
- •Subject has received 2 or fewer prior therapies for his/her chronic lymphocytic leukemia.
- •Subject does not currently require blood transfusions.
- •Subject's peripheral blood leukocyte count is > 10,000 cells/mm
- •Subject's Karnofsky performance status is > 60%.
- •Subject's life expectancy is at least 3 months.
- •Female subjects of childbearing potential (i.e., women who have not been surgically sterilized or have not been post-menopausal for at least 1 year), and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception throughout the entire study period.
- •Subject is willing and able to comply with the prescribed treatment protocol and evaluations.
排除标准
- •Subjects will be ineligible for study participation if they meet any of the following criteria:
- •Subject received biologic therapy and/or chemotherapy that may be active against chronic lymphocytic leukemia within the 4 weeks prior to Study Day
- •Subject is anticipated to require steroid therapy within the next 21 days.
- •Subject received an investigational (i.e., experimental) therapy within the 4 weeks prior to Study Day
- •Subject's clinical laboratory values meet any of the following criteria within the 7 days prior to Study Day 1:
- •Platelet count < 25,000 cells/mm3
- •Absolute neutrophil count < 500 cells/mm3
- •Hemoglobin < 8.0 g/dL and with an autoimmune hemolytic component to the subject's anemia
- •AST and/or ALT > 2.5 X the upper limit of normal
- •Total bilirubin > 1.5 X the upper limit of normal
- •Serum creatinine > 2 mg/dL
- •Subject has a known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C infection.
- •Subject has a clinically relevant active infection and/or a serious co-morbid medical condition, such as recent myocardial infarction, unstable angina, difficult-to-control congestive heart failure, uncontrolled hypertension, difficult-to-control cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, cirrhosis, inflammatory bowel disease.
- •Subject had major surgery within the 4 weeks prior to Study Day
- •Subject had another malignancy within the 3 years prior to study entry, with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer, or other cancer for which the subject has been disease-free for at least 3 years.
- •If female, subject is pregnant or breast-feeding.
- •Subject has a concomitant disease or condition, including laboratory abnormalities, which in the opinion of the Investigator could interfere with the conduct of the study or could put the subject at unacceptable risk.
研究组 & 干预措施
GCS-100
Experimental
GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
干预措施: GCS-100 (Drug)
结局指标
主要结局
To Evaluate the effect of GCS-100 on markers of apoptosis in subjects with chronic lymphocytic leukemia using physical examinations, vital signs, lab assessments, and adverse event reporting
时间窗: Up to 15 cycles X 21 days
次要结局
- To evaluate the effect of GCS-100 on peripheral blood leukocyte count in subjects with chronic lymphocytic leukemia using complete blood count, leukocyte count and circulating cells for apoptosis(Hour 6 after Day 1 dosing, and Days 4 and 8)
研究者
研究点 (8)
Loading locations...
相似试验
终止
1 期
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaNCT02034227Spirogen6
已完成
2 期
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3Non-Alcoholic Steatohepatitis (NASH)NCT02466516Gilead Sciences72
已完成
2 期
Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on TreatmentChronic Hepatitis BNCT02174276Gilead Sciences195
进行中（未招募）
2 期
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104Paroxysmal Nocturnal HemoglobinuriaNCT05476887Kira Pharmacenticals (US), LLC.35
已完成
2 期
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsInfluenzaNCT05606965ModernaTX, Inc.172